purpose of the copy tests will be to examine whether alternative disclosures can improve consumer understanding of mortgage terms and help to reduce potential deception about mortgage offers. The findings from the focus groups and interviews will be used in developing the alternative disclosures used in the copy tests.

All information will be collected on a voluntary basis and consumers will receive usual and customary compensation for their participation. For the qualitative research the FTC has contracted with a consumer research firm to locate eligible borrowers, recruit respondents, moderate the focus groups, conduct the interviews, and write a report of the findings. For the quantitative research the FTC has also contracted with a consumer research firm to locate eligible borrowers and recruit respondents as well as to conduct the copy tests and write a brief methodological report. The results will assist the FTC in determining how required disclosures and other information affects consumers' ability to understand the cost and features of mortgages. This understanding will further the FTC's mission of protecting consumers and competition in this important market.

2. Estimated Hours Burden

Qualitative Research

The contractor will recruit 12 consumers for each focus group, with the expectation that each group will be comprised of 8–10 participants. Each focus group will take two hours. Thus, the focus group research will impose a burden of up to 40 hours (2 groups × 10 participants per group × 2 hours per participant). Approximately 36-one-hour long, in-depth interviews will be conducted. If all respondents are single decision makers, this would amount to a 36-hour burden. However, some of the interviews may include couples. Assuming that half of the interviews include couples (the upper bound offered by the contractor), the hours burden for the in-depth interviews would increase to 54 hours ((18 × 2 hours) + (18 × 1 hour)). The cumulative burden for the qualitative research will range from 76 hours to 94 hours.

Quantitative Research

Approximately 800 consumers who engaged in a mortgage transaction during the previous year will participate in the quantitative phase of the research. Each copy test interview will take roughly 20–30 minutes. The estimated hours burden for the quantitative research ranges from 267 hours (800 respondents × ⅓ hour per respondent) to 400 hours (800 respondents × ½ hour per respondent).

Total

The total estimated hours burden for both phases of the study ranges from 343 hours (76 hours + 267 hours) to 494 hours (94 hours + 400 hours).

3. Estimated Cost Burden

Participants will be compensated financially for their participation, as recommended and budgeted for by the contractor. Participation is voluntary and will not require start-up, capital, or labor expenditures by respondents.

By direction of the Commission.

C. Landis Plummer,

Acting Secretary.

[FR Doc. 03–9852 Filed 4–21–03; 8:45 am]

BILLING CODE 0750–01–M

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entities
Transactions Granted Early Termination—03/24/2003			
20030458	Fiserv, Inc	Bruce Christensen	Precision Computer Systems, Inc.
20030462	General Atlantic Partners 76, L.P	SSA Investor, LLC	SSA Global Technologies, Inc.
20030469	Cooperatieve Centrale Raiffeisen-Boerenleenbank B.A.	Southeast Timber, Inc	Southeast Timber, Inc.
20030470	International Paper Company	Southeast Timber, Inc	Southeast Timber, Inc.
Transactions Granted Early Termination—03/25/2003			
20030421	Johnson & Johnson	Grunenthal Pharma GmbH & Co. KG	Gruenthal GmbH.
20030448	Philadelphia Suburban Corporation	DQE, Inc	AcquaSource Development Company. Aqua Source Operations, Inc. AquaSource Utility, Inc. The Reynolds Group, Inc.
Transactions Granted Early Termination—03/26/2003			
20021081	A. Jerrold Perenchio	Hispanic Broadcasting Corporation	Hispanic Broadcasting Corporation. Univision Communications, Inc.
20030419	Behrman Capital III, L.P	ILC Industries, Inc	ILC Industries, Inc.
20030457	Artal Group S.A	Florine Mark	The WW Group, Inc.

Trans #	Acquiring	Acquired	Entities
Transactions Granted Early Termination—03/27/2003			
20030375	L–3 Communications Holdings, Inc	Goodrich Corporation	Goodrich Aerospace Component Overhaul & Repair, Inc. Goodrich Avionics Systems, Inc. Goodrich FlightSystems, Inc.
Transactions Granted Early Termination—03/28/2003			
20030484	The Riverside Company	VS&A Communications Partners II, L.P	ExpoExchange, LLC.
20030488	MidMark Equity Partners II, L.P	Davis Industries, Inc	Davis Industries, Inc.
Transactions Granted Early Termination—04/01/2003			
20030471	Perry Ellis International, Inc	Salant Corporation	Salant Corporation.
20030475	Citigroup Inc	Worldspan, L.P	Worldspan, L.P
Transactions Granted Early Termination—04/02/2003			
20030452	Taylor & Francis Group plc	Information Holdings Inc	CRC Press (UK) LLC. CRC Press LLC. The Parthenon Publishing Group Inc.
20030459	Societe Wallonne de Gestion et de Participations, S.A.	Duferco Participation Holding Limited	Duferco U.S. Investment Corp.
20030464	Johnson & Johnson	Scios Inc	Scios Inc.
20030472	CBRE Holding, Inc	Insignia Financial Group, Inc	Insignia Financial Group, Inc.
20030476	Liz Claiborne, Inc	Pamela Skaist-Levy and Jeffrey Levy	Travis Jeans, Inc.
20030480	Blum Strategic Partners, L.P	CBRE Holding, Inc	CBRE Holding, Inc.
20030481	Blum Strategic Partners II, L.P	CBRE Holding, Inc	CBRE Holding, Inc.

For Further Information Contact: Sandra M. Peay, Contact Representative or Renee Hallman, Legal Technician, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H–303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 03–9853 Filed 4–21–03; 8:45 am]

BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

[File No. 021 0192]

Pfizer Inc. and Pharmacia Corporation; Analysis to Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed Consent Agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before May 14, 2003.

ADDRESSES: Comments filed in paper form should be directed to: FTC/Office of the Secretary, Room 159–H, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580. Comments filed in electronic form should be directed to: consentagreement@ftc.gov, as prescribed below.

FOR FURTHER INFORMATION CONTACT: Elizabeth Jex, FTC, Bureau of Competition, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580, (202) 326–3273.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46(f), and Section 2.34 of the Commission's Rules of Practice, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for April 14, 2003), on the World Wide Web, at ''http://www.ftc.gov/os/2003/04/index.htm.'' A paper copy can be obtained from the FTC Public Reference Room, Room 130–H, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580, either in person or by calling (202) 326–2222.

Public comments are invited, and may be filed with the Commission in either paper or electronic form. Comments filed in paper form should be directed to: FTC/Office of the Secretary, Room 159–H, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580. If a comment contains nonpublic information, it must be filed in paper form, and the first page of the document must be clearly labeled ''confidential.'' Comments that do not contain any nonpublic information may instead be filed in electronic form (in ASCII format, WordPerfect, or Microsoft Word) as part of or as an attachment to email messages directed to the following email box: consentagreement@ftc.gov. Such comments will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission's Rules of Practice, 16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order to Aid Public Comment

The Federal Trade Commission (''Commission'') has accepted, subject to final approval, an Agreement Containing Consent Orders (''Consent Agreement'') from Pfizer Inc. (''Pfizer'') and Pharmacia Corporation (''Pharmacia'') which is designed to remedy the anticompetitive effects of the acquisition of Pharmacia by Pfizer. Under the terms of the proposed